SUMMARY OF FINANCIAL PERFORMANCE: FULL YEAR 2018 VS FULL YEAR 2017
• The Company delivered revenue of $25.6 million for the financial year ending 31December 2018, up 20% year on year versus total group revenue of $21.4 million in2017.
• The majority of revenue growth was driven by ADAPT® sales which grew 55% yearon year to $11.1 million, compared to $7.2 million in 2017.
• Revenue from the Infusion business was $14.5 million, up 2% year on year.
• Underlying growth in the Infusion business, excluding revenues from Go Medical,was stronger. Revenue was up 24% from $9.0 million in 2017, to $11.2 million.
• Selling, general and administration expenses (SG&A), which includes R&D spend,was $34.3 million for 2018. In 2018, SG&A costs for ADAPT® have declined as apercentage of revenue from 142% to 122%.
• Gross profit for the group for the year was $12.4 million representing a gross profitmargin of 49%.
• Net loss after tax was $24.7 million.
• The closing cash balance on 31 December 2018 was $12.0 million up from $8.3million on 31 December 2017.
- Forums
- ASX - By Stock
- AVR
- Ann: Preliminary Final Report for period to 31 December 2018
Ann: Preliminary Final Report for period to 31 December 2018, page-2
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$18.31 |
Change
0.000(0.00%) |
Mkt cap ! $351.9M |
Open | High | Low | Value | Volume |
$18.30 | $19.00 | $18.00 | $363.4K | 19.82K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 500 | $18.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.50 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 500 | 18.130 |
1 | 300 | 18.110 |
1 | 50 | 18.080 |
1 | 200 | 18.050 |
1 | 1000 | 18.000 |
Price($) | Vol. | No. |
---|---|---|
18.500 | 1000 | 1 |
19.000 | 438 | 1 |
19.290 | 325 | 1 |
19.800 | 264 | 1 |
19.870 | 202 | 1 |
Last trade - 15.59pm 01/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online